Prescription Drug Pricing Policy Changes and What They Mean for Employers

Prescription drug pricing policy is again a headline issue in U.S. health policy under the second Trump administration. From a Most-Favored-Nation executive order, to the launch of TrumpRx.gov, the federal government has signaled an intent to reshape how prescription drugs are priced and purchased in America. For employers that sponsor health plans, the key question is not political but practical. How might these changes affect pharmacy spending, benefit design, fiduciary responsibility, and long-term cost trends?

While the direct impact on employer-sponsored plans is still evolving, the policy direction is clear. Pricing pressure, transparency requirements, and alternative purchasing channels are increasing. Employers should understand what has changed in prescription drug pricing policy and what remains uncertain.

What Is Changing? And what does Most-Favored-Nation (MFN) Pricing mean?

On May 12, 2025, the White House issued an Executive Order directing manufacturers to offer Most-Favored-Nation pricing to the United States. As outlined in the accompanying White House fact sheet, MFN pricing is defined as aligning U.S. prices with the lowest price paid in comparably developed foreign countries.

The administration has since begun entering targeted MFN-style agreements with major manufacturers on selected drugs, particularly in Medicaid and certain direct-to-consumer channels. These agreements are not blanket price reductions across all medications. They apply to specific products and programs, including some high-profile therapies such as GLP-1 medications.

The policy goal is to reduce U.S. drug prices and, in some cases, reduce reliance on intermediaries. However, broader application to the commercial employer market would require additional regulatory steps and potentially further negotiation with manufacturers.

Direct-to-Consumer Access Through TrumpRx

TrumpRx.gov launched in early 2026. Major news coverage and policy analysis describe it as a federal portal that allows consumers to compare offers and then purchase certain drugs for cash through manufacturer or partner pharmacy sites at discounted prices. To clarify, it is not an online pharmacy,

At present, TrumpRx primarily serves cash-only consumers and reflects certain MFN-aligned pricing initiatives. It does not operate within standard employer plan claim flows or typical PBM contracting structures. While future integration with private coverage is possible, the current employer plan’s impact appears limited.

PBM Transparency and Reform Efforts

There has also been a strong federal push for transparency from pharmacy benefit managers. A 2025 Executive Order and subsequent rulemaking efforts aim to increase disclosure of PBM compensation, rebates, and spread pricing practices. Recent reforms and proposed rules require more detailed reporting to employer health plans on utilization, gross and net spending, and compensation data, particularly in the large-group and Medicare markets.

Independent analyses by organizations such as KFF have noted that increased PBM reporting and rebate transparency could significantly change how employers evaluate pharmacy benefit contracts. These efforts are focused less on immediate price reductions and more on visibility into how drug pricing flows through the benefit chain.

Medicare Negotiation Under the Inflation Reduction Act

The Medicare Drug Price Negotiation Program created under the Inflation Reduction Act remains in place. Rather than replacing it, the current administration has layered MFN initiatives and TrumpRx policies on top of that existing framework.

Discussions about expanding or modifying Medicare negotiations continue, but concrete changes that would directly alter employer-sponsored commercial plans have not yet been finalized. Any broader shifts in Medicare pricing could influence market pricing over time, though the timing and magnitude remain uncertain.

What Employers Should Understand/The Impact on Employer-Sponsored Plans Remains Uncertain

Many of these prescription drug policy initiatives require detailed regulatory implementation over multiple years. Employer advisory firms consistently describe the near-term impact on commercial plans as directional rather than immediate.

Most employer-facing changes are expected to phase in over several plan years, not all at once. Employers should view current policy developments as indicators of long-term structural change rather than immediate cost relief.

Falling Drug Prices Do Not Automatically Reduce Employer Costs

Even if prices decline in Medicare or cash-pay channels, employer plans may not see parallel savings.

Policy analysts and employer advisers highlight several risks:

• Manufacturers may adjust rebates or pricing structures in commercial markets to offset discounts provided elsewhere.
• Employer plans typically pay negotiated net prices through PBM contracts, which can differ significantly from public list prices or cash-pay discounts.
• Changes in rebate flows or compensation structures can alter plan economics in complex ways.

For employers, the real question is not whether prices fall in one segment of the market. It is how those changes affect net cost, rebate arrangements, and contractual obligations within their own plans.

Transparency as Both Opportunity and Responsibility

As prescription drug pricing policy shifts toward greater transparency, employers gain more data but also greater fiduciary expectations under ERISA.

Legal commentary has emphasized that when employers receive new data on PBM compensation, rebates, or spread pricing, they are expected to carefully evaluate that information. Failure to monitor fees or address potential conflicts of interest could expose plan sponsors to increased litigation risk.

Plan sponsors should:

• Understand total PBM compensation, not just out-of-pocket costs.
• Evaluate whether rebates, spread pricing, and administrative fees align with plan goals.
• Consider alternative contracting structures such as pass-through or flat-fee models where appropriate.
• Benchmark contracts and performance against independent standards.

Increased transparency does not reduce employer responsibility. It raises the bar for oversight.

Why Proactive Pharmacy Benefit Management Matters More Than Ever

In a shifting policy environment, employers who take a passive approach to pharmacy spending may find themselves reacting to pricing shifts rather than managing them strategically.

Proactive strategies may include:

• Rigorous PBM performance evaluation and contract benchmarking.
• Exploring pass-through or flat-fee PBM arrangements.
• Implementing clinical utilization controls for high-cost therapies.
• Monitoring emerging direct-to-consumer channels, including manufacturer cash-pay programs and TrumpRx, for potential implications in plan design.

These strategies are widely recommended by benefits consultants and employer advisory groups. They position employers to respond thoughtfully as policies evolve.

How TriBridge Partners Supports Employers

Policy headlines can create noise. Employers still need to deliver affordable, accessible benefits while controlling long-term costs.

At TriBridge Partners, we help employers:

• Interpret how drug pricing policy changes may affect plan design and pharmacy spending.
• Strengthen PBM oversight and contract alignment.
• Integrate pharmacy strategy into broader benefits and total rewards planning.
• Educate stakeholders on how pricing shifts could affect employee costs, utilization, and retention.

We approach pharmacy benefits as a strategic lever within overall talent and risk management strategy.

Staying Ahead of Prescription Drug Pricing Policy Changes

Prescription drug pricing policy will continue to generate headlines. As recent White House announcements, KFF analyses, and employer advisory briefings make clear, the direction of policy is toward increased pricing pressure and greater transparency. The timeline and magnitude of employer impact, however, will unfold gradually.

Employers do not need to wait for Washington to act. By focusing on transparency, contractual oversight, and value-driven benefit design, plan sponsors can protect both their plans and their people regardless of how federal policy evolves.

If you would like help assessing how emerging drug pricing policies could affect your pharmacy strategy or benefits costs, TriBridge Partners can help you move forward with clarity and confidence.